The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Dec

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns

Data Published on Incidence of Immune Checkpoint Inhibitor-Associated ITP

Lymphocyte Kinetics After CAR T Infusion Predict Survival Outcomes in Non-Hodgkin Lymphoma

CD123-Targeting ADC Shows Activity in AML and BPDCN